Thrombolytic Therapy in Arterial Disease. I: Available Agents

Loscalzo J. An overview of thrombolytic agents. Chest 1990; 98: 117S–23S.

Sixma JJ Wester J. The hemostatic plug. Semin Hematol 1977; 14: 265–99.

Nachman RL Leung LLK . Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. Clin Invest 1982; 69: 263–69.

Owen WG Esmon CT . Functional properties of an endothelial cell co-factor for thrombin-catalyzed activation of protein C. J Biol Chem 1981; 256: 5532–35.

Lorand L Konishi K. Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys 1965; 105: 58–64.

van Hinsbergh VWM Sprengers ED Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost 1987; 57: 148–53.

MacFarlane RD . Hemostasis: Introduction. Br Med Bull 1977; 33: 183–94.

Muller JE Tofler GH Stone PH . Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733–43.

Shattil SJ Anaya-Galindo R Bennett J Colman RW Cooper RA . Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1976; 55: 636–43.

Naftilan A Dzau VJ Joscalzo J. Abnormalities of membrane structure and function in essential hypertension. Hypertension 1986; 11: 174–79.

Barger AC Beeuwkes R III Lainey LL Silverman KJ . Hypothesis: Vasa vasorum and neovascularization of human coronary arteries. N Engl J Med 1984; 310: 175–77.

Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77–89.

Sherry S. Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J 1981; 102: 1134–39.

Sherry S. Streptokinase pharmacology and its application to acute myocardial infarction. Vasc Med 1983; 1: 64–76.

Rijken DC Collen DC . Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035–41.

Dosne AM Dupuy E Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978; 12: 377–87.

Suenson E Petersen LC . Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta 1986; 870: 510–19.

Nossel HL Wasser J Kaplan KL LaGamma KS . Sequence of fibrinogen proteolysis and platelet release after intra uterine infusion of hypertonic saline. J Clin Invest 1979; 64: 1371–78.

Whitaker AN Elms MJ Masci PP Bundessen PG . Measurement of cross-linked fibrin derivatives in plasma. J Clin Pathol 1984; 37: 882–87.

Marder VJ Budzynski AZ . Degradation products of fibrinogen and cross-linked fibrin projected clinical applications. Thromb Diasthes Haemorrh 1974; 32: 49–56.

Francis CW Connaghan DG Marder VJ . Assessment of fibrinolytic therapy for acute myocardial infarction. Circulation 1986; 74: 1027–36.

Eisenberg PR Sherman LA Perez J. Jaffe AS . Relationships between plasma levels of cross-linked fibrin degradation products and clinical presentation of patients wtih acute myocardial infarction. Thromb Res 1987; 46: 109–20.

Seifried E Tanswell P Rijken DC Kluft C Hougee E. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction. Lancet 1987; 2: 333–34.

Brenner B Francis CW Fitzpatrick PG Rothbard RL . Relation of plasma D-Dimer concentrations to coronary artery reperfusion before and after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 1989; 63: 1179–84.

Francis CW Connaghen DG Scott WL Marder VJ . Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75: 1170–77.

Mentzer RL Budzynski AZ Sherry S. High-dose brief-duration intravenous infusion of streptokinase in acute myocardial infarction: Description of effect in the circulation. Am J Cardiol 1986; 57: 1220–26.

Verstraete M Vermylen J Amery A Vermylen C. Thrombolytic therapy with streptokinase using a standard dosage schedule. Br Med J 1966; 1: 454–56.

Jalihal S Morris GK . Antistreptokinase titres after intravenous streptokinase. Lancet 1990; 335: 184–86.

Lynch M Littler WA Pentecost BL Stockley RA . Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Br Heart J 1990; 66: 139–42.

White HD Cross DB Williams BF Norris RM . Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J 1990; 64: 177–81.

Elliott J Cross D Cederholm-William S White H. High streptokinase titres 4 years after administration of intravenous streptokinase. New Zealand Cardiac Society Meeting, August 1991.

Werkheiser WC Markus G. The interaction of streptokinase with plasminogen. J Biol Chem 1965; 239: 2655–50.

Neuhof H Hey D Glaser E Wolf H Lasch HG . Haemodynamic reactions induced by streptokinase therapy in patients with acute myocardial infarction. Eur J Int Care Med 1975; 1: 21–30.

Smith RAG Dupe RJ English PD Green J. Fibrinolysis with acyl enzymes: A new approach to thrombolytic therapy. Nature 1981; 290: 505–508.

Matsuo O Collen D Verstraete M. On the fibrinolytic and thrombolytic properties of active site P-anisoylated streptokinase plasminogen compex (BRL 26921). Thromb Res 1981; 24: 347–58.

Smith RAG Dupe RJ English PD Green J. Acyl enzymes asthrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemost 1982; 47: 269–74.

Dupe RJ English PD Smith RAG Green J. Acyl enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism. Thromb Haemost 1984; 51: 248–53.

Prowse CV Hornsey V Ruckley CV Boulton FE . The comparison of acylated streptokinase plasminogen complex and streptokinase in healthy volunteers. Thromb Haemost 1982; 47: 132–35.

Nunn B Esmail E Fears R Ferres H Standring R. Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans. Drugs 1987; 33 (suppl 3): 88–92.

Been M de Bono DP Muir AL . Clinical effects and kinetic properties of intravenous anistreplase — anisoylated plasminogen-streptokinase activator complex (BL 26921) in acute myocardial infarction. Int J Cardiol 1986; 11: 53–61.

Kohler M Hellstern P Doenecke P . High dose systemic streptokinase and acylated streptokinase-plasminogen comlex (BRL 26921) in acute myocardial infarction: Alteration of the fibrinolytic system and clearance of fibrinolytic activity. Haemostasis 1987; 17: 32–39.

Gemmill JD Hogg KJ Burns JMA . Comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. Br J Clin Pharmacol 1991; 31: 143–47.

Ferres H Hibbs M Smith RAG . Deacylation studies in vitro on Anisoylated Plasminogen Streptokinase Activator Complex. Drugs 1987; 33 (suppl 3): 80–82.

Staniforth DH Smith RAG Hibbs M. Streptokinase and anisoylated streptokinase plasminogen complex, their action on haemostasis in human volunteers. Eur J Clin Pharmacol 1983; 24: 751–56.

Walker ID Davidson JF Ray AP Hutton I Lawrie TDV . Acylated streptokinase plasminogen complex in patients with acute myocardial infarction. Thromb Haemost 1984; 52: 204–206.

Hoffmann JJML Van Rey FJW Bonnier JJRM . Systemic effects of BRL 26921 during thrombolytic therapy of acute myocardial infarction. Thromb Res 1985; 37: 567–72.

Andrassy K Ritz E. Biochemie and klinische Bedeutung von Urokinase. Dtsch Med Wochenschr 1978; 103: 1015.

Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77.

Duckert F. Biochemie der Urukinase. Folia Haematol (Leipz) 1971; 95: 131.

Marder VJ Sherrys Thrombolytic therapy; the current status. N Engl J Med 1988; 318: 1512–20.

Holmes WE Pennica D Blaber M. Cloning and expression of the gene for prourokinase in E. coli. Biotechnology 1985; vmr-3: 923.

Camiolo SM Thorsen S Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activator human globulin and plasmin. Proc Soc Exp Biol Med 1971; 138: 277.

Pannell R Gurewich V. Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215.

Harpel PC Chang TS Verderber E. Tissue plasminogen activator and urokinase mediate the binding of glu-plasminogen to plasma fibrin l. J Biol Chem 1985; 270: 4432.

Rakoci J Wiman B Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta 1978; 540: 295.

Flohe L. Single-chain urokinase-type plasminogen activators: New hopes for clot specific lysis. Eur Heart J 1985; 6: 905–908.

Holmes WE Pennica D Blaber M . Cloning and expression of the gene for prourokinase in Escherichia coli. Biotechnology 1985; vmr-3: 923.

Gunzler WA Cramer J Frankus E . Chemical enzymological and pharmacological equivalence of urokinase isolated from genetically transformed bacteria and human urine. Arzneimittel forschung/Drug Res 1985; 35: 652–62.

Zamarron C Lijnen HR van Hoef B . Biological and thrombolytic properties of proenzyme and active forms of human urokinase-1, fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemost 1984; 52: 19.

Gurewich V Pannell R Louie S . Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase) — a study in vitro and in two animal species. J Clin Invest 1984; 73: 1731.

Wun T-C Schleuning W-D Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276.

Ichinose A Fujikawa K Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486.

Lijnen R Zamarron C Blaber M . Activation of plasminogen by pro-urokinase. J Biol Chem 1986; 262: 1253.

Lijnen HR Collen D. Simulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator. Thromb Res 1986; 43: 687.

Collen D Zamarron C Lijnen HR . Activation of plasminogen by pro-urokinase — II kinetics. J Biol Chem 1986; 261: 1259.

Trubestein G Popov S Wolf H . Effects of prourokinase and urokinase on the fibrinolytic system in man. Haemostasis 1987; 17: 238.

van de Werf F Vanhaecke J de Geest H . Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74: 1066.

Pannell R Gurewich V. Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215.

Wallen P Bergsdorf N Ranby M. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity absorption on fibrin. Biochim Biophys Acta 1982; 719: 318–28.

Rijken EC Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035–41.

Pennica D Holmes WE Kohr WJ . Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214–21.

Strassburger W Wollmer A Pitts JE . Adaptation of plasminogen activator sequences to known protease structures. FEBS Lett 1983; 157: 219–23.

Banyai L Vardi A Patthy L. Common evolutionary origin of the fibrin-binding structures of fibrinoectin and tissue-type plasminogen activator. FEBS Lett 1983; 163: 37–41.

Rijken DC Holyaerts M Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator, J Biol Chem 1982; 257: 2920–25.

Loskutoff DJ Edginton T. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977; 74: 3903–907.

Rijken DC Wijngaards G Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815–30.

Loskutoff DJ Van Mourik JA Erickson LA Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1984; 80: 2956–60.

Christensen U Holmberg L Bladh B Astedt B. Kinetics between urokinase an inhibitor of fibrinolysis from placental tissue. Thromb Haemost 1982; 48: 24–26.

Kruithof EK Ransijn A Bachmann F. Inhibition of tissue plasminogen activator by human plasma. In: Davidson JF Bachmann F Bouvier CA Kruithof IKO eds. Progress in fibrinolysis, Edinburgh: volume VI. Churchill Livingstone, 1983: 362–66.

Chmielewska J Ranby M Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 131: 427–36.

Korninger C Stassen JM Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemost 1982; 46: 658–61.

Smalling RW Schumacher R Morris D . Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. Am Coll Cardiol 1990; 15: 915–21.

Gemmill JD Hogg KJ Macintyre PD . A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. Br Heart J 1991; 66: 134–39.

Tranchesi B Chamone DF Cobbaert C van de Werf F. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction. Am J Cardiol 1991; 68: 161–65.

Neuhaus K Feuerer W Jeep-Tebbe S . Improved thrombolysis with a modified dose regimen of recombinant tissue type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566–69.

Von Essen R , on behalf of the TPAS Investigators. Presentation at George Washington University Symposium, Dallas, Texas, USA, November 1990.

Grines CL Nissen SE Booth DC . And the KAMIT Study Group. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase A: A pilot study. J Am Coll Cardiol 1989; 14: 573–80.

Bode C Schuler G Nordt T . Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue type plasminogen activator in acute myocardial infarction. Circulation 1990; 81: 907–13.

Collen D Mao J Stassen JM . Thrombolytic properties of Lys-158 mutants of recombinant single chain urokinase-type plasminogen activator in rabbits with jugular vein thrombosis. J Vasc Med Biol 1989; 1: 46–49.

Neilles L Lijnen HR Collen D . Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 or urokinase-type plasminogen activator. J Biol Chem 1987; 262: 10855–62.

Haber H Quertermous T Matsueda GR . Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51–56.

Ganz W. The quest for the ideal reperfusion strategy continues. Circulation 1991; 83: 1818–21.